From the ∗Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
†Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National, Institutes of Health, Bethesda, MD
‡Department of Nuclear Medicine, University Hospital DĂ¼sseldorf, DĂ¼sseldorf
§Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center
∥Translational Lung Research Center Heidelberg, German Center for Lung Research
¶National Center for Tumor Diseases, Heidelberg, Germany.
Received for publication March 18, 2021; revision accepted May 28, 2021.
Conflicts of interest and sources of funding: Patent application for PSMA-1007 for F.L.G., U.H., and J.C. and for PSMA-617 for C.Kr. and U.H. F.L.G. is an advisor at SOFIE Biosciences, Telix, and ABX pharmaceutical. The remaining authors declare no conflicts of interest.
Authors’ contributions: K.D., A.M., and F.L.G. contributed to the data selection and interpretation. K.D. and A.M. drafted the work. C.Kr., P.L.C., C.Kl., J.C., and U.H. substantively revised the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate: The radiopharmaceutical was used on an individual patient basis according to German Pharmaceuticals Act §13(2b). The patient gave written informed consent to receive the novel diagnostics and permitted anonymized publication of related medical data. The ethical committee of Heidelberg University approved this retrospective evaluation to be in accordance with the Helsinki declaration. For case reports from clinical practice, no trial registration is required.
Correspondence to: Katharina Dendl, Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120 Heidelberg, Germany. E-mail: [email protected].
